Bruton tyrosine kinase | Tec family | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

Bruton tyrosine kinase

target has curated data in GtoImmuPdb

Target id: 1948

Nomenclature: Bruton tyrosine kinase

Abbreviated Name: Btk

Family: Tec family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 659 Xq21.33-q22 BTK Bruton tyrosine kinase
Mouse - 659 X E3 Btk Bruton agammaglobulinemia tyrosine kinase
Rat - 660 X q34 Btk Bruton tyrosine kinase
Previous and Unofficial Names
AGMX1 | ATK | B-cell progenitor kinase | IMD1 | PSCTK1 | xid | X-linked immune deficiency | Bruton agammaglobulinemia tyrosine kinase
Database Links
BRENDA
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
Orphanet
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containing compound
PDB Id:  3GEN
Resolution:  1.6Å
Species:  Human
References:  27
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834
PDB Id:  4OTF
Ligand:  GDC-0834
Resolution:  1.95Å
Species:  Human
References:  40
Enzyme Reaction
EC Number: 2.7.10.2

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
RN486 Hs Inhibition 9.5 pKd 36
pKd 9.5 (Kd 3.1x10-10 M) [36]
WZ4002 Hs Inhibition 7.4 pKd 42
pKd 7.4 (Kd 4.3x10-8 M) [42]
acalabrutinib Hs Inhibition >8.0 pEC50 4
pEC50 >8.0 (EC50 <1x10-8 M) [4]
BMS-986195 Hs Inhibition 10.0 pIC50 24
pIC50 10.0 (IC50 1.1x10-10 M) [24]
Description: Evaluated in a FLIPR calcium mobilisation assay in Ramos B lymphocytes.
BTK inhibitor 4b Hs Inhibition 9.4 pIC50 20
pIC50 9.4 (IC50 3.9x10-10 M) [20]
Description: Inhibition of unactivated (non-phosphorylated) BTK in vitro.
abivertinib Hs Inhibition 9.4 pIC50 37
pIC50 9.4 (IC50 4x10-10 M) [37]
Description: In a biochemical assay.
spebrutinib Hs Inhibition >9.3 pIC50 15
pIC50 >9.3 (IC50 <5x10-10 M) [15]
BMS-986142 Hs Inhibition 9.3 pIC50 33
pIC50 9.3 (IC50 5x10-10 M) [33]
BTK inhibitor 16 [PMID: 30122225] Hs Inhibition 9.1 pIC50 30
pIC50 9.1 (IC50 7x10-10 M) [30]
Description: Using a microfluidic, off-chip mobility shift kinase assay with FITC-AHA-EEPLYWSFPAKKK-NH2 as peptide substrate.
vecabrutinib Hs Inhibition 9.1 pIC50 18
pIC50 9.1 (IC50 7.3x10-10 M) [18]
Description: Biochemical assay measuring inhibition of phosphorylation of a fluorescein-labeled polyGAT peptide, in the presence of active BTK enzyme, ATP, and inhibitor.
ibrutinib Hs Inhibition 8.8 – 9.3 pIC50 8,29
pIC50 9.3 (IC50 5x10-10 M) [29]
pIC50 8.8 (IC50 1.5x10-9 M) [8]
CNX-774 Hs Inhibition >9.0 pIC50 3
pIC50 >9.0 (IC50 <1x10-9 M) [3]
example 6 [WO2015079417A1] Hs Inhibition 9.0 pIC50 2
pIC50 9.0 (IC50 1x10-9 M) [2]
Description: Inhibition of hBTK in a biochemical enzyme assay measuring BTK-mediated phosphorylation of a peptide substrate.
PRN1008 Hs Inhibition 8.8 pIC50 28
pIC50 8.8 (IC50 1.5x10-9 M) [28]
Description: Measured in a caliper-based kinase assay, to assess inhibition of recombinant human BTK kinase activity (@ 16 μM ATP) using the phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2.
CGI1746 Hs Inhibition 8.7 pIC50 12
pIC50 8.7 (IC50 1.9x10-9 M) [12]
compound 9 [PMID: 26006010] Hs Inhibition 8.7 pIC50 7
pIC50 8.7 (IC50 1.9x10-9 M) [7]
compound 36 [PMID: 21958547] Hs Inhibition 8.7 pIC50 21
pIC50 8.7 (IC50 1.93x10-9 M) [21]
zanubrutinib Hs Inhibition 8.7 pIC50 32
pIC50 8.7 (IC50 2x10-9 M) [32]
Description: Inhibition of the enzymatic activity of recombinant human BTK in a TR-FRET assay.
compound 2c [PMID: 24900538] Hs Inhibition 8.5 pIC50 31
pIC50 8.5 (IC50 3.5x10-9 M) [31]
tirabrutinib Hs Inhibition 8.4 pIC50 38
pIC50 8.4 (IC50 4x10-9 M) [38]
compound 38 [PMID: 24915291] Hs Inhibition >8.4 pIC50 22
pIC50 >8.4 (IC50 <4.4x10-9 M) [22]
compound 31 [PMID: 24915291] Hs Inhibition 8.4 pIC50 22
pIC50 8.4 (IC50 5x10-9 M) [22]
acalabrutinib Hs Inhibition 8.3 pIC50 8
pIC50 8.3 (IC50 5.1x10-9 M) [8]
DD-03-171 Hs Inhibition 8.3 pIC50 13
pIC50 8.3 (IC50 5.1x10-9 M) [13]
Description: Inhibition of kinase activity in a biochemical assay.
compound 25 [PMID: 31260299] Hs Inhibition 8.3 pIC50 39
pIC50 8.3 (IC50 5.3x10-9 M) [39]
GDC-0834 Hs Inhibition 8.2 pIC50 40
pIC50 8.2 (IC50 6x10-9 M) [40]
PRN694 Hs Inhibition 7.8 pIC50 41
pIC50 7.8 (IC50 1.7x10-8 M) [41]
CHMFL-BTK-11 Hs Irreversible inhibition 7.6 pIC50 35
pIC50 7.6 (IC50 2.682x10-8 M) [35]
poseltinib Hs Inhibition >7.3 pIC50 9
pIC50 >7.3 (IC50 <5x10-8 M) [9]
Description: Biochemical assay result. Binned IC50 value provided in patent.
evobrutinib Hs Inhibition >7.0 pIC50 17
pIC50 >7.0 (IC50 <1x10-7 M) [17]
Description: Binned value derived from a time-dependent BTK enzyme assay.
example #30 (S) [WO2014210255A1] Hs Inhibition >7.0 pIC50 6
pIC50 >7.0 (IC50 <1x10-7 M) [6]
Description: Inhibition of BTK catalytic domain as measured using TR-FRET based detection of phosphorylated peptide Biotin-(Ahx)-GAEEEIYAAFFA-COOH,
CGI560 Hs Inhibition 6.4 pIC50 25
pIC50 6.4 (IC50 4x10-7 M) [25]
LFM-A13 Hs Inhibition 4.8 pIC50 26
pIC50 4.8 (IC50 1.72x10-5 M) [26]
Description: IN a cell-free BTK assay using BTK immunoprecipitated from B18.2 cells.
fenebrutinib Hs Inhibition - - 10
[10]
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 11,34

Key to terms and symbols Click column headers to sort
Target used in screen: BTK
Ligand Sp. Type Action Value Parameter
dasatinib Hs Inhibitor Inhibition 8.9 pKd
bosutinib Hs Inhibitor Inhibition 8.3 pKd
NVP-TAE684 Hs Inhibitor Inhibition 7.6 pKd
lestaurtinib Hs Inhibitor Inhibition 7.2 pKd
foretinib Hs Inhibitor Inhibition 7.1 pKd
JNJ-28312141 Hs Inhibitor Inhibition 7.1 pKd
neratinib Hs Inhibitor Inhibition 6.8 pKd
tamatinib Hs Inhibitor Inhibition 6.7 pKd
staurosporine Hs Inhibitor Inhibition 6.7 pKd
PD-173955 Hs Inhibitor Inhibition 6.7 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx


Reference: 1,16

Key to terms and symbols Click column headers to sort
Target used in screen: BTK/BTK
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
dasatinib Hs Inhibitor Inhibition 2.1
EGFR/ErbB-2/ErbB-4 inhibitor Hs Inhibitor Inhibition 2.9 47.0 16.0
Lck inhibitor Hs Inhibitor Inhibition 4.6 1.0 1.0
bosutinib Hs Inhibitor Inhibition 5.7
staurosporine Hs Inhibitor Inhibition 7.8 2.5 -1.0
K-252a Hs Inhibitor Inhibition 8.9 -1.0 -1.0
GSK-3 inhibitor IX Hs Inhibitor Inhibition 13.1 1.0 0.0
vandetanib Hs Inhibitor Inhibition 17.6
Gö 6976 Hs Inhibitor Inhibition 22.0 10.0 9.0
indirubin derivative E804 Hs Inhibitor Inhibition 24.1 12.0 -2.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Immunopharmacology Comments
The TEC family protein tyrosine kinases have been identified as key components of T-cell-receptor activation and signalling. TEC family kinases are expressed predominantly by haematopoietic cells. T cells express ITK, TXK and TEC [5]. BTK is expressed by all hematopoietic cells, except T cells and differentiated plasma cells.
As BTK is an important mediator of critical B-cell pro-survival mechanisms including apoptosis, cell adhesion, and migration, it has been identified as a drug target for pharmaceutical intervention in B cell malignancies. BTK is the target of several small molecule tyrosine kinase inhibitors, including the approved anti-leukemia drug ibrutinib and several others in the development pipeline.
BTK also plays an essential role in B cell receptor (BCR)-mediated signaling, Fcγ receptor signaling in monocytes, and Fcε receptor signaling in mast cells and basophils. All of these functions have been implicated in the pathophysiology of autoimmune disease, making BTK inhibition a valid strategy for the management of autoimmune diseases.
Cell Type Associations
Immuno Cell Type:  B cells
Comment:  BTK is essential for B lymphocyte development, differentiation and signalling, playing an important role in the function of innate immune cells and the adaptive immune response. BTK is involved in cytokine signalling and is a component of the Toll-like receptors (TLR) pathway (linking TLR activation to induction of NF-κB, and downstream cytokine regulation).
References:  14,19
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 5 GO processes
GO:0002755 MyD88-dependent toll-like receptor signaling pathway TAS
GO:0045087 innate immune response TAS
click arrow to show/hide IEA associations
GO:0001805 positive regulation of type III hypersensitivity IEA
GO:0001812 positive regulation of type I hypersensitivity IEA
GO:0002553 histamine secretion by mast cell IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 5 GO processes
GO:0002250 adaptive immune response IBA
GO:0002721 regulation of B cell cytokine production TAS
click arrow to show/hide IEA associations
GO:0001805 positive regulation of type III hypersensitivity IEA
GO:0001812 positive regulation of type I hypersensitivity IEA
GO:0002344 B cell affinity maturation IEA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 9 GO processes
GO:0002250 adaptive immune response IBA
GO:0002721 regulation of B cell cytokine production TAS
GO:0002902 regulation of B cell apoptotic process TAS
GO:0042113 B cell activation TAS
GO:0045579 positive regulation of B cell differentiation TAS
click arrow to show/hide IEA associations
GO:0001805 positive regulation of type III hypersensitivity IEA
GO:0001812 positive regulation of type I hypersensitivity IEA
GO:0002344 B cell affinity maturation IEA
GO:0030889 negative regulation of B cell proliferation IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 9 GO processes
GO:0002721 regulation of B cell cytokine production TAS
GO:0002755 MyD88-dependent toll-like receptor signaling pathway TAS
GO:0038095 Fc-epsilon receptor signaling pathway TAS
GO:0045579 positive regulation of B cell differentiation TAS
GO:0050852 T cell receptor signaling pathway IBA
GO:0050853 B cell receptor signaling pathway IBA
click arrow to show/hide IEA associations
GO:0001805 positive regulation of type III hypersensitivity IEA
GO:0001812 positive regulation of type I hypersensitivity IEA
GO:0030889 negative regulation of B cell proliferation IEA
Immuno Process:  Immune system development
GO Annotations:  Associated to 2 GO processes
GO:0045579 positive regulation of B cell differentiation TAS
click arrow to show/hide IEA associations
GO:0002344 B cell affinity maturation IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 3 GO processes
GO:0002721 regulation of B cell cytokine production TAS
click arrow to show/hide IEA associations
GO:0001818 negative regulation of cytokine production IEA
GO:0098761 cellular response to interleukin-7 IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 9 GO processes
GO:0002755 MyD88-dependent toll-like receptor signaling pathway TAS
GO:0038095 Fc-epsilon receptor signaling pathway TAS
GO:0042113 B cell activation TAS
GO:0045579 positive regulation of B cell differentiation TAS
GO:0050852 T cell receptor signaling pathway IBA
GO:0050853 B cell receptor signaling pathway IBA
click arrow to show/hide IEA associations
GO:0002344 B cell affinity maturation IEA
GO:0002553 histamine secretion by mast cell IEA
GO:0030889 negative regulation of B cell proliferation IEA
Clinically-Relevant Mutations and Pathophysiology
Disease:  Agammaglobulinemia, X-linked
Synonyms: Bruton-type agammaglobulinemia [Disease Ontology: DOID:14179]
Disease Ontology: DOID:14179
OMIM: 300755
Orphanet: ORPHA47
Disease:  Isolated growth hormone deficiency, Type III
Synonyms: Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia
OMIM: 307200
Orphanet: ORPHA632
General Comments
The history, and pros and cons of the various small molecule BTK inhibitor classes that have been developed for clinical applications, and prospects for future drug design are reviewed by Liang et al. (2018) [23].

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Angst D, Gessier F, Vulpetti A. (2015) Novel amino pyrimidine derivatives. Patent number: WO2015079417A1. Assignee: Novartis Ag. Priority date: 29/11/2013. Publication date: 04/06/2015.

3. Barf T, Kaptein A. (2012) Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem., 55 (14): 6243-62. [PMID:22621397]

4. Barf TA, Jans CGJM, Man PADeA, Oubrie AA, Raaijmakers HCA, Rewinkel JBM, Sterrenburg J-G, Wijkmans JCHM. (2014) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk inhibitors. Patent number: US20140155385 A1. Assignee: Barf TA, Jans CGJM, Man PADeA, Oubrie AA, Raaijmakers HCA, Rewinkel JBM, Sterrenburg J-G, Wijkmans JCHM. Priority date: 19/07/2011. Publication date: 05/06/2014.

5. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. (2005) Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol., 23: 549-600. [PMID:15771581]

6. Bonafoux D, Davis HM, Frank KE, Friedman MM, Herold JM, Hoemann MZ, Huntley R, Osuma A, Sheppard G, Somal GK et al.. (2014) Primary carboxamides as BTK inhibitors. Patent number: WO2014210255A1. Assignee: Abbvie Inc.. Priority date: 26/06/2013. Publication date: 31/12/2014.

7. Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V et al.. (2015) Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat. Chem. Biol., 11 (7): 525-31. [PMID:26006010]

8. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 374 (4): 323-32. [PMID:26641137]

9. Cha MY, Kang SJ, Kim MR, Lee JY, Jeon JY, Jo MG, Kwak EJ, Lee KO, Ha TH, Suh KH, Kim MS. (2011) Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity. Patent number: WO2011162515A2. Assignee: Hanmi Holdings Co. , Ltd.. Priority date: 23/06/2010. Publication date: 29/12/2011.

10. Crawford JJ, Ortwine DF, Wei B, Young WB. (2013) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity. Patent number: WO2013067274. Assignee: Genentech, Inc.. Priority date: 03/11/2011. Publication date: 10/05/2013.

11. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

12. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE et al.. (2011) Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol., 7 (1): 41-50. [PMID:21113169]

13. Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES et al.. (2019) Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood, 133 (9): 952-961. [PMID:30545835]

14. Doyle SL, Jefferies CA, Feighery C, O'Neill LA. (2007) Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J. Biol. Chem., 282 (51): 36953-60. [PMID:17932028]

15. Evans E, Tester R, Aslanian S, Mazdiyasn H, Ponader S, Tesar B, Chaturvedi P, Nacht M, Stiede K, Witowski S et al.. Clinical Development of AVL - 292: A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies. Accessed on 29/10/2014. Modified on 29/10/2014. http://www.celgene.com, http://www.celgene.com/content/uploads/pdf/2011_ASH_AVL-292.pdf

16. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

17. Hodous B, Liu-Bujalski L, Jones R, Bankston D, Johnson TL, Mochalkin I, Nguyen N, Qiu H, Goutopoulos A, Brugger N. (2012) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity. Patent number: WO2012170976. Assignee: Merck Patent Gmbh. Priority date: 10/06/2011. Publication date: 13/12/2012.

18. Hopkins BT, Conlon P, Chan TR, Jenkins TJ, Cai X, Humora M, Shi X, Miller RA, Thompson A. (2013) Pyrimidinyl tyrosine kinase inhibitors. Patent number: WO2013185084A1. Assignee: Biogen Idec Ma Inc., Sunesis Pharmaceuticals, Inc.. Priority date: 08/06/2012. Publication date: 12/12/2013.

19. Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, Brennan FM, Webster D, Foxwell BM. (2006) Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J. Immunol., 176 (6): 3635-41. [PMID:16517732]

20. Kawahata W, Asami T, Kiyoi T, Irie T, Taniguchi H, Asamitsu Y, Inoue T, Miyake T, Sawa M. (2018) Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis. J. Med. Chem., 61 (19): 8917-8933. [PMID:30216722]

21. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al.. (2011) Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett., 21 (21): 6258-63. [PMID:21958547]

22. Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z. (2014) Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J. Med. Chem., 57 (12): 5112-28. [PMID:24915291]

23. Liang C, Tian D, Ren X, Ding S, Jia M, Xin M, Thareja S. (2018) The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Eur J Med Chem, 151: 315-326. [PMID:29631132]

24. Liu Q, Watterson SH, Batt DG, Ahmad S, Bertrand MB, Gong H, Guo W, Macor JE, Ngu K, Tebben J, Tino A. (2016) Indole carboxamide compounds. Patent number: US20160115126A1. Assignee: Bristol-Myers Squibb Co. Priority date: 24/10/2014. Publication date: 28/04/2016.

25. Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM. (2012) Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J. Med. Chem., 55 (10): 4539-50. [PMID:22394077]

26. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, Uckun FM. (1999) Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J. Biol. Chem., 274 (14): 9587-99. [PMID:10092645]

27. Marcotte DJ, Liu YT, Arduini RM, Hession CA, Miatkowski K, Wildes CP, Cullen PF, Hong V, Hopkins BT, Mertsching E et al.. (2010) Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci., 19 (3): 429-39. [PMID:20052711]

28. Owens T, Verner E. (2014) PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS. Patent number: WO2014039899. Assignee: Principia Biopharma. Priority date: 06/09/2013. Publication date: 13/03/2014.

29. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG et al.. (2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem, 2 (1): 58-61. [PMID:17154430]

30. Qiu H, Liu-Bujalski L, Caldwell RD, Follis AV, Gardberg A, Goutopoulos A, Grenningloh R, Head J, Johnson T, Jones R et al.. (2018) Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Bioorg. Med. Chem. Lett., 28 (17): 2939-2944. [PMID:30122225]

31. Wang T, Lamb ML, Block MH, Davies AM, Han Y, Hoffmann E, Ioannidis S, Josey JA, Liu ZY, Lyne PD et al.. (2012) Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett, 3 (9): 705-9. [PMID:24900538]

32. Wang Z, Guo Y. (2016) Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators. Patent number: US9447106B2. Assignee: Beigene Ltd.. Priority date: 25/04/2013. Publication date: 20/09/2016.

33. Watterson SH, De Lucca GV, Shi Q, Langevine CM, Liu Q, Batt DG, Beaudoin Bertrand M, Gong H, Dai J, Yip S et al.. (2016) Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers. J. Med. Chem., 59 (19): 9173-9200. [PMID:27583770]

34. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

35. Wu H, Huang Q, Qi Z, Chen Y, Wang A, Chen C, Liang Q, Wang J, Chen W, Dong J et al.. (2017) Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Sci Rep, 7 (1): 466. [PMID:28352114]

36. Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A et al.. (2012) RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther., 341 (1): 90-103. [PMID:22228807]

37. Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B, Xu R, Fang X, Liu J, Fang C et al.. (2016) AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. Mol. Cancer Ther., 15 (11): 2586-2597. [PMID:27573423]

38. Yamamoto S, Yoshizawa T. (2011) Purinone derivative. Patent number: WO2011152351. Assignee: Ono Pharmaceutical Co., Ltd.. Priority date: 31/05/2010. Publication date: 08/12/2011.

39. Yao X, Sun X, Jin S, Yang L, Xu H, Rao Y. (2019) Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. J. Med. Chem., 62 (14): 6561-6574. [PMID:31260299]

40. Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Gallion S, Hymowitz SG, Kropf JE, Lee SH et al.. (2015) Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834. Bioorg. Med. Chem. Lett., 25 (6): 1333-7. [PMID:25701252]

41. Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A et al.. (2015) Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. J. Biol. Chem., 290 (10): 5960-78. [PMID:25593320]

42. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R et al.. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 462 (7276): 1070-4. [PMID:20033049]

How to cite this page

Tec family: Bruton tyrosine kinase. Last modified on 08/11/2019. Accessed on 14/11/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948.